Categories of scientific evidence for off-label indication
When the evidence of off-label use of tocilizumab in a specific indication is approved in foreign countries, that is classified as category I. If the indication is recommended by Up To Date/ Micromedex (I/IIa/IIb) or authoritative society guideline, that is classified as category II. When the indication is supported by systematic review, RCT, cohort study, non-randomized controlled study, expert consensus, that is classifed as category III. If the indication is supported by case series report or case report, that is classified as category IV. The category V is the indication without medical evidences support.